Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 4/20 | 0.31 |
| ▸ | HTR1D | P28221 | 4/20 | 0.31 |
| ▸ | HTR1A | P08908 | 3/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898321 | 0.91 | HTR2A (0.41) | HTR2AKCNJ1KCNH2TAAR1DRD2 | |
| SCHEMBL299763 | 0.84 | HTR2A (0.45) | HTR2AKCNJ1KCNH2TAAR1ALDH1A1 | |
| SCHEMBL299742 | 0.79 | HTR2A (0.34) | HTR2AKCNJ1KCNH2DRD2HTR1D | |
| SCHEMBL300052 | 0.79 | GPR119 (0.40) | KCNJ1KCNH2ALDH1A1 | |
| SCHEMBL2894905 | 0.75 | MEN1 (0.35) | HTR2AKCNJ1KCNH2KDM4EALDH1A1 | |
| SCHEMBL296779 | 0.74 | MTNR1A (0.40) | HTR2ATAAR1DRD2HTR1DHTR1A | |
| SCHEMBL13028050 | 0.74 | KCNJ1 (0.53) | KCNJ1KCNH2 | |
| SCHEMBL4606848 | 0.73 | BCHE (0.42) | KDM4EALDH1A1 | |
| SCHEMBL2895014 | 0.72 | KCNJ1 (0.69) | KCNJ1KCNH2 | |
| SCHEMBL10993273 | 0.72 | KCNN2 (0.44) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | HTR2A 3252/4885KCNJ1 2/4885KCNH2 16/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | HTR2A 3252/4885KCNJ1 2/4885KCNH2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.